Neurophysiology Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract - Neurophysiology Research (2020) Volume 0, Issue 0

Anti-β2-Glycoprotein I Autoantibody Expression as a Potential Biomarker for Strokes in Patients with Anti-Phospholipid Syndrome

This study sought to determine the frequency rates of anti- cardiolipin (aCL) dependent on the presence of β2-GPI, anti-β2-glycoprotein I (aβ2-GPI), and anti-phosphatidyl serine (aPS) IgG autoantibodies among stroke patients, and thus demonstrate the importance of testing for aβ2-GPI autoantibodies. All cases were under 50 years-of-age and had no recognizable risk factors. Using ELISA to evaluate the presence of IgG isotype of aCL, aβ2-GPI, and aPS autoantibodies in their blood, the results indicated that the frequency of aβ2-GPI was 14/50 (28%), aCL was 11/50 (22%), and aPS was 9/50 (18%) among stroke patients. In contrast, aCL was detected in 2/30 (6.7%) of control subjects; each of the other anti- phospholipid antibodies (APLA) was never observed. Of all the aβ2-GPI+ cases, the incidence of stroke patients having the combined profile of aβ2-GPI + aCL was 11/14 (78.6%) and of aβ2-GPI + aPS was 9/14 (64.3%). Only 2/14 (14.3%) of these aβ2-GPI+ patients also expressed aCL in the absence of aPS. The frequency of patients expressing all three markers was only 9/14 (64.3 %). In none of the APS/stroke patients were aCL or aPS expressed in the absence of the aβ2-GPI. Conversely, aβ2- GPI as a sole marker was seen in 3/14 (21.4%) of these patients (i.e., in absence of either other marker). It was concluded from these studies that the among the three major forms of APLA examined, the presence of aβ2-GPI IgG autoantibodies appeared to correlate best with stroke in patients who were concurrently suffering APS.

Author(s): Husham Bayazed

Abstract Full Text PDF